The company has received approval from the USFDA for its abbreviated new drug application (ANDA) Olopatadine Hydrochloride ophthalmic solution USP, 0.1 per cent, Alembic Pharmaceuticals said in a filing to BSE.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2B56UwB
via IFTTT
0 comments:
Post a Comment